– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention –

– Partnership Advances Gilead’s Global Access Strategy, Helping Turn Scientific Innovation into Public Health Impact –

Gilead Sciences, Inc. (NASDAQ:GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led efforts toward adoption and implementation, as part of the broader efforts to end the epidemic across the region.

Key Highlights

  • Marks a major milestone within Gilead’s broader global lenacapavir access strategy.
  • Establishes a regional pathway across all PAHO Member States in Latin America and the Caribbean to support broader country-led efforts toward adoption and implementation.
  • Combines PAHO’s regional coordination and procurement capabilities with Gilead’s access strategy to enable sustainable scale-up.

The agreement with PAHO builds on Gilead’s longstanding scientific and access efforts to address HIV incidence in Latin America and the Caribbean, where new infections increased by 13% between 2010 and 2024 and gaps in PrEP utilization exist. Those efforts include the PURPOSE 2 trial, which evaluated the efficacy and safety of twice-yearly lenacapavir for PrEP and form part of Gilead's broader commitment to expanding prevention access across the region.

Today’s announcement provides a new access pathway for 14 countries outside of Gilead’s lenacapavir voluntary licensing agreements, complementing existing generic access pathways across the region. Together, these tailored approaches help broaden access to lenacapavir for PrEP across Latin America and the Caribbean. These countries are Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela.